Leadership appointments at PTC Therapeutics

17 April 2020

New Jersey, USA-based rare disease drug developer PTC Therapeutics (Nasdaq: PTCT) today announced the appointments of Matthew Klein to chief development officer and Eric Pauwels to chief business officer.

Dr Klein will be responsible for the development of our clinical stage programs. As the CBO, Mr Pauwels will be responsible for PTC’s customer facing activities with health care providers, patients and payers ensuring that our therapies are available and accessible to rare disease patients and their families worldwide.

"I am very pleased to announce these well-deserved appointments to PTC's Executive Committee," said Stuart Peltz, chief executive of PTC Therapeutics, adding: "Matt and Eric are both recognized industry leaders with demonstrated track records of success. In their new roles, they will continue to advance our development pipeline, fuel our company's growth and deliver on our mission to develop and provide transformative therapies for patients living with rare disorders."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK